stg-001
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2020 (NCT04489511)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Plasma retinol-binding proteinINHIBITOR
RBP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CCn1ccc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1- Mol. weight
- 352.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650305 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04489511 | Phase 2 | Oct 1, 2020 | Stargazer Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stargazer Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1